Health
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses – Business Wire
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations. The company presented the results in an oral presentation at the 28th Conference on Retroviruses and Opportunistic Infections (CROI) and published the positive findings of high binding affinity to the variants in preprint server, bioRxiv…
-
Noosa News9 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News10 hours agoMotorcyclist dies in crash with truck
-
General24 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News10 hours agoSomerville House investigating after teachers’ dossier on students leaked